Teva loses its potency

The pharmaceuticals company has a rough fourth quarter and faces continued uncertainty with 2 manufacturing plants.

By Jim J. Jubak Feb 25, 2011 2:26PM
Jim JubakWhen a "buy" no longer enjoys the strengths that made it a buy, you should sell it.

I think that’s now the case with Teva Pharmaceutical Industries (TEVA). I’m selling it out of my Jubak's Picks portfolio today.

The company’s recent earnings stumble -- fourth-quarter 2010 earnings came in 6.3% below fourth-quarter 2009 earnings -- and the continued uncertainty about when Teva’s Copaxone will see generic competition are certainty significant worries about the stock.

But what really bothers me -- what goes to the heart of why I bought Teva in the first place -- are the manufacturing problems the company has had with its Irvine, Calif., and Jerusalem plants. Teva voluntarily shut down the Irvine plant after receiving a warning letter from the U.S. Food and Drug Administration. The company is planning on reopening the plant in March.

Post continues after video:
Investors hoping that this was a one-time problem involving an older plant were disappointed when the FDA opened an inquiry into the company’s new Jerusalem plant in October. That concern turned to worry when the FDA decided that the company’s response wasn’t sufficient and issued a warning letter. The Jerusalem plant makes generic versions of Ambien, among other drugs.

One plant with problems is a mistake. Two plants with problems raise questions about management and company standards.

The two incidents are particularly troubling to me, because one of the reasons to own Teva instead of other generic drug makers is the company’s reputation for high manufacturing standards. The ability to routinely manufacture generics to a high standard of quality looks likely to get even more important -- and more valuable -- under the FDA’s new rules for generic versions of biotech drugs, also called biosimilars.

If Teva’s reputation for quality has been compromised, there’s less reason to own the stock.

Right now, that’s an open question -- but one that carries a substantial element of risk with it. And my calculations don’t give me enough potential upside to offset this risk.

I get a target price of about $56 a share by the end of 2011. With the stock trading at $50.17 as I write this, that means I’m looking at roughly a 12% gain to that target. That’s just not the kind of gain I’d need to take on the risk in this stock.

As of Feb. 25, I’m selling these shares with a 1.8% loss, since I added them to this portfolio on Oct. 13, 2009 at $51.08.

At the time of this writing, Jim Jubak didn't own shares of any companies mentioned in this post in personal portfolios. The mutual fund he manages, Jubak Global Equity Fund (JUBAX), may or may not own positions in any stock mentioned. The fund did not own shares of Teva Pharmaceutical Industries as of the end of January. For a full list of the stocks in the fund as of the end of the most recent quarter, see the fund's portfolio here. 

Related Reading:



Copyright © 2014 Microsoft. All rights reserved.

Fundamental company data and historical chart data provided by Morningstar Inc. Real-time index quotes and delayed quotes supplied by Morningstar Inc. Quotes delayed by up to 15 minutes, except where indicated otherwise. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by Morningstar Inc.


StockScouter rates stocks from 1 to 10, with 10 being the best, using a system of advanced mathematics to determine a stock's expected risk and return. Ratings are displayed on a bell curve, meaning there will be fewer ratings of 1 and 10 and far more of 4 through 7.

123 rated 1
262 rated 2
480 rated 3
651 rated 4
649 rated 5
629 rated 6
616 rated 7
496 rated 8
346 rated 9
111 rated 10

Top Picks

TAT&T Inc9



Top Stocks provides analysis about the most noteworthy stocks in the market each day, combining some of the best content from around the MSN Money site and the rest of the Web.

Contributors include professional investors and journalists affiliated with MSN Money.

Follow us on Twitter @topstocksmsn.